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Abstract
Characteristic features of chronic pancreatitis (CP) may be absent on standard imaging studies. 
Quantitative Magnetic Resonance Imaging (MRI) techniques such as T1 mapping, extracellular 
volume (ECV) fraction, diffusion-weighted imaging (DWI) with apparent diffusion coefficient 
map (ADC), MR elastography (MRE), and T1-weighted signal intensity ratio (SIR) have shown 
promise for the diagnosis and grading severity of CP. However, radiologists still use the 
Cambridge classification which is based on traditional ductal imaging alone. There is an urgent 
need to develop new diagnostic criteria that incorporate both parenchymal and ductal features of 
CP seen by MRI/MRCP. Designed to fulfill this clinical need, we present the MINIMAP study, 
which was funded in September 2018 by the National Institutes of Health. This is a comprehensive 
quantitative MR imaging study which will be performed at multiple institutions in well-
phenotyped CP patient cohorts. We hypothesize that quantitative MRI/MRCP features can serve as 
valuable non-invasive imaging biomarkers to detect and grade CP. We will evaluate the role of T1 
relaxometry, ECV, T1-weighted gradient echo SIR, MRE, arteriovenous enhancement ratio, ADC, 
pancreas volume/atrophy, pancreatic fat fraction, ductal features, and pancreatic exocrine output 
following secretin stimulation in the assessment of CP. We will attempt to generate a multi-
parametric pancreatic tissue fibrosis (PTF) scoring system. We anticipate that a quantitative 
scoring system may serve as a biomarker of pancreatic fibrosis; hence this imaging technique can 
be used in clinical practice as well as clinical trials to evaluate the efficacy of agents which may 
slow the progression or reverse measures of CP.
Keywords
Chronic pancreatitis; MRI; MRCP; T1 mapping; Extracellular volume; Diffusion-weighted 
imaging; MR elastography
Background
The histologic hallmarks of CP include fibrosis, chronic inflammation, and loss of acinar 
cells [1]. Characteristic features of chronic pancreatitis (CP) are often absent on standard 
diagnostic tests, including imaging studies. Indeed, Magnetic Resonance 
Cholangiopancreatography (MRCP) and/or Endoscopic Retrograde 
Cholangiopancreatography (ERCP) can be normal in patients with early disease, and 
diagnosis of early CP remains a challenge [2, 3]. Histologic diagnosis is rarely pursued, 
given the potential for complications (i.e., acute pancreatitis). Endoscopic ultrasound (EUS) 
and ERCP offer only a structural rather than a functional assessment of the pancreas and are 
less reliable in early CP. The sensitivity of available functional tests (fecal elastase and 
chymotrypsin, pancreolauryl and bentiromide tests, breath tests using radiolabeled 
pancreatic substrates) are inadequate in defining mild or moderate pancreatic disease [2, 4]. 
Serum pancreatic enzyme levels (amylase, lipase) are often normal in CP, and these may be 
of limited utility or clinical relevance in these patients. Endoscopic pancreatic function tests 
(ePFT) utilize a hormonal secretagogue such as secretin to maximally stimulate pancreatic 
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secretion, followed by collection and analysis of the fluid, and may detect a decrease in this 
output long before exocrine insufficiency is manifested clinically [2]. Performance of the 
ePFT to date has typically been limited to tertiary referral centers, and while it has been used 
as a surrogate gold standard for the diagnosis of CP [2, 5], it may not be as sensitive [6]. It is 
much desired to have a practical, accessible, highly innovative, reproducible, and non-
invasive imaging method to detect and quantify CP. The major role of the MR imaging has 
been to provide ductal imaging information to the clinicians in a non-invasive fashion. 
Several MR imaging techniques have been shown to be useful for detection of parenchymal 
changes seen with CP; however, there have not been widely accepted MRI-based diagnostic 
criteria that have emerged from these efforts that can potentially combine ductal and 
parenchymal imaging findings.
Objectives
Our primary objective is to evaluate quantitative MRI imaging techniques as a non-invasive 
tool for evaluation of CP. We will assess several functional MR parameters which detect loss 
of proteinaceous content, restricted water diffusion, increased extracellular matrix, and 
stiffness of the parenchyma in addition to MR ductal imaging. We will evaluate the role of 
quantitative MR imaging metrics in differentiating patients with CP from patients with no 
pancreas disease. Review of recent literature data shows promise in this regard, with an 
increase in T1 relaxation time, higher ECV, reduced SIR, reduced ADC, delayed phase 
enhancement, and decreased duodenal fluid volume in response to secretin stimulation seen 
in patients with CP. On the other hand, very limited data exist in subjects without pancreas 
disease as the control population. MINIMAP will enroll healthy volunteers as the control 
cohort and will attempt to validate the results of existing literature. Furthermore, we will 
combine findings on these parameters to generate a multi-parametric pancreas tissue fibrosis 
(PTF) score to quantify the features of pancreatic fibrosis. In the absence of histologic 
confirmation for CP, selection of appropriate cohorts is crucial, as described in SUBJECTS 
AND METHODS. Data generated from this study may potentially offer targets for use to 
study the outcome(s) of novel treatments.
Subjects and methods
Study organization
The consortium for the study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer 
(CPDPC), is supported by a cooperative agreement grant (DK108323) funded by the 
National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK). A major goal of the CPDPC is to improve diagnostic methods 
and treatment of CP, recurrent acute pancreatitis, and pancreatic cancer. The participating 
sites, the organizational structure of the CPDPC, and its studies are provided in a separate 
publication [7], and can also be found online at http://cpdpc.mdanderson.org. MINIMAP 
was funded by the NIDDK (R01DK116963) in September 2018 as a multi-institutional 
prospective ancillary study within the CPDPC.
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We will be recruiting a subset of adults who are participating in the CPDPC longitudinal 
cohort study on CP: Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and 
Translational Studies (PROCEED) [8] (NCT03099850). Subjects with no pancreas disease 
(controls) and patients with suspected or definite CP who meet the inclusion and exclusion 
criteria will be approached for potential participation in MINIMAP. Eligibility criteria are 
defined in Table 1. Enrollment will take place at 7 consortium clinical centers: Indiana 
University Health (primary site hosting the core imaging lab) in Indianapolis, IN; University 
of Pittsburgh Medical Center in Pittsburgh, PA; Ohio State University in Columbus, OH; 
Mayo Clinic Campus in Rochester, MN; Stanford University in Stanford, CA; Cedars-Sinai 
Medical Center and University of California at Los Angeles in Los Angeles, CA.
The CPDPC investigators agreed upon using the Cambridge classification based on MRI/
MRCP and computed tomography (CT) to assess morphological changes in the pancreas, 
and to separate subjects into three groups, referred to as Green zone, Yellow zone, and Red 
zone as described below (Fig. 1). PROCEED investigators follow imaging guidelines 
recently published by the American Pancreatic Association [3]. These criteria are based on 
Cambridge classification, however adapted to use MRI/MRCP and CT to categorize the 
patients. A total of 180 subjects from the PROCEED study will be enrolled in one of the 
following:
a. Control group (Green zone; n = 60). These no pancreatic disease control subjects 
will have no personal history of pancreatic disease or upper abdominal symptoms 
and will qualify as American Society of Anesthesiologists (ASA) physical status 
class 1–2. Age and sex distribution of participants will be pre-defined to match 
the expected distribution of patients within suspected or definite CP groups.
b. Suspected CP group (Yellow zone; Cambridge grade 1 or 2; n = 60). These are 
subjects with indeterminate CP, one episode of acute pancreatitis in the 
preceding 18 months, or recurrent acute pancreatitis. This is a high-risk group for 
progression to definite CP and may be well suited for intervention studies aiming 
at slowing disease progression.
c. Definite CP (Red zone; Cambridge grade 3 or 4; n = 60). These are subjects with 
obvious morphologic features of CP. This group provides an opportunity to 
understand the prevalence and progression of functional and morphological 
changes and complications of the disease.
The rationale for assigning subjects into three groups was previously described in the 
PROCEED methodology paper [8]. The reporting standards and imaging guidelines for use 
in CPDPC studies (excluding MINIMAP) are also reported in a separate paper and will not 
be discussed here [9]. All subjects enrolling in PROCEED will be asked to provide blood, 
urine, saliva, and a stool sample per biospecimen standard operating procedures [10]. A 
subset will undergo a clinical or research EUS or esophagogas-troduodenoscopy (EGD) 
during which pancreas fluid will be collected from the duodenum after injection of secretin 
for biomarker analysis.
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Imaging guidelines and parameters are detailed in Tables 2 and 3, respectively. MRCP will 
include 3D isotropic thin-slice and 2D thick-slice MRCP before and after administration of 
secretin (ChiRhoStim, ChiRhoClin Inc., Burtonsville, MD). T1 relaxation times of tissues 
measured on varying magnetic signal strengths are expected to be different [11]. In this pilot 
study, all MRI examinations will be performed on 1.5T scanners at each study site. In a 
future study with a larger patient population, both 1.5T and 3T magnet strengths will be 
used.
All sites will acquire T1 maps using dual flip-angle spoiled gradient echo (SPGR) sequence. 
It is necessary to standardize the quantitative imaging across different institutions and MR 
manufacturers using a T1 phantom in order to obtain T1 maps as uniform and accurately as 
possible. In this study, we will use a commercially available unit (System phantom model 
130, High Precision Device, Inc.,) which includes an array of multiple elements. These 
elements are 20 mm spheres filled with solutions of T1 ranging from 20 ms to 2000 ms, and 
T1 values have been verified by the National Institute of Standards and Technology (NIST). 
Optimization to the dual flip-angle SPGR imaging will be made according to the phantom 
test results in each institution (Fig. 2). Correction for B1 field inhomogeneity will be 
incorporated. At the present time, MRE cannot be performed at all sites due to the scarcity 
of required hardware and software which is currently under development. For MRE, a 3D 
spin-echo echo planar imaging sequence will be employed to obtain 3D wave information 
along with 3D spatial data. As the pancreas is much further away from the anterior 
abdominal wall, shear waves at lower frequency are employed so that the shear waves reach 
the pancreas. Pancreas MRE at 40 Hz or 60 Hz provided more reliable stiffness values 
across different parts of pancreas those obtained in a pilot study with 20 normal volunteers 
[12] and also demonstrated the reproducibility of the technique [13]. 40 Hz is the preferred 
frequency for MRE of the pancreas.
Image reconstruction
The dual flip-angle SPGR image sets will be transferred to the core imaging laboratory at 
Indiana University to reconstruct the T1 maps using the same post-processing software (Fig. 
3). To compute T1 maps, SPGR images acquired using two different flip angles will be 
collected, imported, co-registered (to each other and B1 correction map) using a normalized 
entropy mutual information algorithm [14], and processed according to the following 
equation:
T1map
∗(x, y, z) = − TR ∕ ln
IFA1
(x, y, z)




sin(FA2 ∗ B1corr(x, y, z))
IFA1
(x, y, z)




tan(FA2 ∗ B1corr(x, y, z))
,
where x, y, z, IFA1, IFA2, TR, FA1, and FA2 are the horizontal position, vertical position and 
depth position, signal intensity of SPGR image with Flip Angle 1, signal intensity of SPGR 
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image with Flip Angle 2, repeat time (ms), Flip Angle 1 (in radians), and Flip Angle 2 (in 
radians) used during the data collection [15, 16].
T1 relaxation times obtained from the pancreas and the aortic lumen (blood pool) in 
unenhanced and 6-min delayed contrast-enhanced phases will be used to calculate the ECV 
fraction using the formula
ECVpancreas =
(1 − hematocrit) × ΔR1pancreas
ΔR1blood
,
where ΔR1pancreas and ΔR1blood are defined as the change of 1/T1 relaxation rate in pancreas 
and blood pool relaxivity before and after contrast administration, T1 is a time constant 
describing the longitudinal relaxation rate, and its reciprocal (1/T1) is referred to as R1 (Fig. 
4). The change in R1 (ΔR1) is defined as ΔR1 = (R1post-contrast) – (R1pre-contrast). ΔR1 is 
proportional to Gadolinium (Gd) concentration when both tissues are in equilibrium: 
ΔR1pancrea/ΔR1blood = [Gd]pancreas/[Gd]blood. Since the gadolinium chelates, such as Gd-
BOPTA, are extracellular agents, the ratio of contrast agent concentrations between the 
pancreas and blood equals the ratio of extracellular volume between the tissues: [Gd]pancreas/
[Gd]blood = ECVpancreas/ECVblood. The ECV of the blood is defined as the fraction of the 
blood volume which is not composed of blood cells (i.e., the fraction of plasma). The plasma 
volume is simply calculated as ECVblood = [1 – hematocrit]. Hematocrit level will be 
obtained on the day of MR examination if a recent test result is not available. In MRE, the 
obtained wave images will be directionally and bandpass filtered to remove longitudinal and 
reflected waves. Then the filtered wave images will be inverted to obtain spatial stiffness 
maps of the pancreas as shown in Fig. 5.
Image analysis and data collection
MRCP ductal findings will be recorded by an experienced radiologist using the Cambridge 
classification as the diagnostic standard [17]. An experienced research analyst will perform 
MR data collection following delineating the contours of the pancreas at multiple levels in a 
semi-automated fashion using 3D volumetric image analysis software (Analyze 12.0, 
AnalyzeDirect, Overland Park, KS). Collected data will include T1 relaxation time, T1-
weighted signal intensity of the (pancreas, spleen, and paraspinal muscles) in unenhanced, 
arterial, and 5-min delayed post-contrast phases, ADC value, stiffness of the parenchyma, 
pancreatic volume, diameter (in the head, body, and tail), and water and fat signal fractions 
using T1-weighted DIXON series (Table 4). While making these measurements, special 
attention will be given to avoid volume averaging from the signal retroperitoneal fat, dilated 
pancreatic duct and vessels. The signal intensity ratio of the pancreas to the spleen (SIR p/s) 
and signal intensity ratio of the pancreas to paraspinal muscle (SIR p/m) will be obtained by 
dividing the T1-weighted signal intensity (SI) of the pancreas by the reference organ. T1-
weighted 2-point Dixon technique will be used to calculate the pancreatic fat signal fraction 
(FSF) by entering the SI of the pancreas on the fat-only (SIFat) and water-only (SIWater) 
fractions into the equation: FSFpancreas = SIFat/SIFat + SIWater. The excretory volume of the 
pancreas will be graded on the post-secretin images of the MRCP. The duodenal filling 
grade will be assessed according to the degree of duodenal filling, as follows: Grade 1, 
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pancreatic fluid is confined to the duodenal bulb; Grade 2, fluid fills the second portion of 
the duodenum; Grade 3, fluid fills the third portion of the duodenum; and Grade 4, fluid 
reaches the fourth portion of the duodenum or jejunum [18]. Visceral and subcutaneous fat 
content will be separated manually using image analysis software which will calculate the 
crosssectional volumes of the two abdominal compartments. Visceral adipose tissue (VAT) is 
defined as intra-abdominal fat (including intraperitoneal and retroperitoneal fat) bound by 
parietal peritoneum or transversalis fascia, excluding the vertebral column and the paraspinal 
muscles. The subcutaneous adipose tissue (SAT) is defined as fat superficial to the 
abdominal and back muscles. These two fractions will be used to determine the visceral 
adiposity scale for each subject. Arteriovenous enhancement ratio will be obtained by the 
ratio of signal intensity on the arterial phase and 5-min delayed post-contrast gradient echo 
images. Pancreas diameter will be measured perpendicular to the main pancreatic duct in the 
head, body, and tail on the axial T1-weighted gradient echo image with fat suppression. The 
pancreatic head will be measured at the thickest pancreatic head slice lying on the right side 
of the superior mesenteric vein. Measurement of the pancreatic body will be obtained from 
thickest portion of the gland using the point of intersection between a vertical line along the 
left vertebral body margin and dorsal margin of the pancreas to the ventral margin of the 
pancreas [19]. The tail of pancreas will be measured lateral to the medial margin of the left 
kidney. The main pancreatic duct diameter will be subtracted from the diameter.
Statistical considerations
According to the PRoBE guidelines for biomarker development [20], we will collect pilot 
MRI data in 60 well-phenotyped patients with suspected CP. A similar receiver operating 
characteristic (ROC) analysis as in the primary objective will be conducted to compare this 
group with patients with definite CP. The patients with suspected CP, definite CP, and no 
pancreas disease controls will be compared in a descriptive analysis of patient 
characteristics. The patients with suspected CP are believed to be in an intermediate state 
during the progress to definite CP, and they may be a heterogeneous group. For the primary 
objective, a ROC analysis will be conducted to assess the ability of T1 relaxation time to 
separate (discriminate) definite CP patients from controls. The rationale is that if T1 is a 
specific biomarker for CP, it should usually demonstrate a larger difference from the controls 
than other groups. We propose to assess this ability using the area under the ROC curve 
(AUC). We will select the quantitative MRI metrics with good discrimination ability in the 
ROC analysis of the primary objective and combine them to generate a composite score that 
further improves the discrimination ability of the MRI. The multi-parametric score will be 
developed based on logistic regression of disease group on multiple features. Interaction will 
be incorporated if justified by plausible biological mechanisms, or previous literature or 
improved model performance. The linear predictor of the estimated logistic regression 
model forms the composite score, which will be analyzed in a ROC analysis. We will use 
bootstrap cross-validation to guard against overestimation of AUC due to model overfitting. 
Based on previous publications [21, 22], we expect the AUC to be between 0.80 and 0.94. 
We plan to enroll 60 subjects per group, and we anticipate that ten patients per group may be 
excluded from analysis due to suboptimal quality of the MRI images (e.g., motion artifact, 
patient’s intolerance, or other limitations of the study). Therefore, with 50 patients per group 
available for analysis, the 90% confidence interval of AUC can be estimated with a half-
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width between 0.06 and 0.08, when the true AUC is between 0.80 and 0.87. The half-width 
is smaller for a larger AUC. The results will inform the study design and sample size 
calculation in anticipation of a future larger population study.
Discussion
Establishing a diagnosis of CP at an early stage has tangible benefits to the patient, but 
currently, this remains problematic in clinical practice. The Cambridge classification, which 
was originally developed for ERCP in 1984 [17], has been adopted to MRCP and has 
remained as the de facto diagnostic standard for decades. However, the Cambridge 
classification is a ductal classification system and is less sensitive for the diagnosis of early 
CP. Parenchymal features visualized on MRI have shown promise in establishing the CP at 
an early stage [23] but are not part of the current criteria. As an initial step towards 
establishing an MRI-based classification system, a prospective multi-institutional study is 
needed in well-phenotyped patients. We are presenting MINIMAP as the first 
comprehensive MRI study designed for this purpose.
In addition to evaluating ductal abnormalities, MRI/MRCP imaging techniques can evaluate 
the parenchymal changes related to fibrosis. These MR imaging techniques detect loss of 
proteinaceous water content, restricted water diffusion, increased stiffness, pancreatic ductal 
changes, and changes in the enhancement pattern of the pancreas. Due to the high protein 
content of the normal pancreas, the gland typically appears hyperintense on T1-weighted 
images [24]. In CP, the normal pancreatic parenchyma rich in protein content is reduced, and 
the normal acinar cells become replaced by fibrosis and inflammation [25]. A decreased T1 
signal of the pancreas in CP reflects the degree of fibrosis and loss of normal acinar tissue, 
and therefore holds promise for the diagnosis of CP [21, 26]. T1-weighted signal is assessed 
with signal intensity ratio (SIR) which compares the brightness of the pancreas to a 
reference organ. Decreased SIR of the pancreas has been shown to reflect the degree of 
fibrosis and loss of normal acinar tissue and holds promise for the diagnosis of CP [21, 26]. 
A recent study found a significant positive correlation between pancreatic fluid bicarbonate 
level and SIR of the pancreas to the spleen (p < 0.0001). A lower SIR of the pancreas 
predicted exocrine dysfunction as suggested by endoscopic pancreatic fluid collection [21]. 
A pancreas to splenic SIR threshold of less than 1.2 showed a sensitivity of 77% and 
specificity of 76% for detection of low pancreatic fluid bicarbonate, i.e., pancreatic exocrine 
dysfunction [21].
T1 mapping is a quantitative imaging technique, which allows us to measure the tissue-
specific T1 relaxation time of the tissues and this may be a more reliable and accurate 
method compared with traditional T1-weighted images. T1 mapping has been used reliably 
to diagnose myocardial diseases [27], and has shown promise for detecting fibrosis in 
cirrhosis [28, 29] and CP [22, 23]. Another quantitative MR imaging method interrogates the 
underlying changes to the extracellular matrix that occurs during tissue fibrosis, including 
increases in collagen [30, 31] and proteoglycan [32] concentrations. ECV imaging 
dichotomizes the tissues into intra- and extracellular space and reports the extracellular 
fraction. A recent study performed on 119 patients showed that T1 relaxation time had 64% 
sensitivity and 88% specificity (AUC: 0.80) for diagnosis of CP, while ECV showed 92% 
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sensitivity and 77% specificity [22], while combining ECV and T1 relaxation time yielded 
sensitivity of 85% and specificity of 92% (AUC: 0.94) [22]. In diffusion-weighted imaging 
(DWI), the signal intensity reflects the free motion or diffusion of water molecules. In 
fibrotic tissues, as in CP, the ADC value may be expected to decrease. In a study of 89 
patients with no CP, mild CP, and severe CP (defined by MRCP using Cambridge criteria), 
an ADC of < 179 × 10–5 mm2/sec was helpful for differentiating normal pancreas from CP 
groups [33]. In another study, 29 patients imaged prior to pancreatectomy were found to 
have a pancreas-to-muscle SIR cutoff value of 1.15 on T1-weighted images which yielded a 
sensitivity of 100% and specificity of 95% [34]. MRE of the liver has been shown to be very 
helpful in the evaluation of hepatic fibrosis [35]; however, MRE of the pancreas is still under 
development and not yet commercially available. In a pilot study, using MRE to determine 
pancreatic stiffness, twenty healthy volunteers underwent MRE exams using an 
experimental MRE driver emitting lower frequency vibrations than those used in liver MRE 
imaging [12]. The mean shear stiffness (average of values obtained in different pancreatic 
segments) was (1.15 ± 0.17) kPa at 40 Hz and (2.09 ± 0.33) kPa at 60 Hz [12], while a 
different pilot study on 22 healthy volunteers showed excellent repeatability of this 
technique [13]. MINIMAP will verify whether MRE can provide reproducible stiffness 
measurements throughout the pancreas on different vendor platforms, potentially allowing 
for the assessment of pancreatic fibrosis in well-phenotyped patients. The consequences of 
pancreatic steatosis require further evaluation, and MRI allows for quantitative assessment 
of tissue adipose volume. In a recently published study, a moderate positive correlation 
between pancreatic steatosis and distribution of abdominal adipose tissue was found with the 
highest correlation being with the increasing adiposity within the visceral compartment (r = 
0.54) [36]. Patients with CP showed higher visceral fat (p = 0.01) and pancreatic fat fraction 
(p < 0.001) indicating the presence of an association between visceral adiposity and CP. 
These results demonstrate the ability of MRI to quantify and correlate pancreatic steatosis; 
however, prospective evaluation in a larger cohort of patients is required.
In this study, a dedicated research analyst and an experienced radiologist will perform all 
data collection. A separate CPDPC consortium ancillary study is currently in progress 
evaluating inter- and intra-observer variability in the assessment of CT and MRI/MRCP 
findings of CP (e.g., Cambridge score, excretory volume grading, T1 signal). MINIMAP was 
designed with predominantly quantitative imaging techniques in mind, to minimize 
subjective assessment. Accordingly, we expect the interobserver agreement to be 
satisfactory.
In conclusion, MINIMAP is the first and most comprehensive MRI study performed at 
multiple institutions in well-phenotyped cohorts of patients with suspected or definite CP as 
well as healthy subjects. This study may establish that MRI is an excellent tool for non-
invasive evaluation of CP and assessment of pancreatic fibrosis. We anticipate that we will 
be able to develop a user-friendly multi-parametric pancreatic tissue fibrosis (PTF) scoring 
system. The results of MINIMAP may impact the outcome of future studies, which may 
identify treatments that change the natural history of CP as well as predict chronic 
pancreatitis progression and early pancreatic cancer.
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MINIMAP subject enrollment. This study will enroll subjects from the PROCEED study. 
Subjects will be separated into three groups, referred to as Control (Green zone), Suspected 
CP (Yellow zone), and Definite CP (Red zone). There will be total of 60 subjects in each 
group
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Phantom testing and protocol optimization will be performed as each institution before 
imaging of study subjects. a. This is a T1 image created using the T1 phantom. Each small 
sphere represents the measured T1 of the elements within the T1 phantom. The elements are 
20 mm spheres filled with solutions of T1 ranging from 20 ms to 2000 ms and values have 
been verified by the National Institute of Standards and Technology (NIST). b. Results of 
phantom testing at study sites. Optimization to the dual flip-angle SPGR parameters will be 
made for each institution according to the phantom test results
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Acquisition of T1 maps using dual flip-angle spoiled gradient echo (SPGR) technique. This 
is a 58-year-old male who presented with abdominal pain. Acquired images (a and b) will be 
transferred to the core imaging lab to reconstruct the T1 maps (c and d). Flip angle #1 and #2 
will vary depending on phantom testing performed at each institution. (P Pancreas, K Left 
Kidney, L Liver, S Spleen). a. Axial SPGR image acquired using a flip angle #1. b. Axial 
SPGR image acquired using a flip angle #2. c. Reconstructed T1 map from the two axial 
SPGR images shown in Fig. 1a and b. This is a grayscale T1 map on which region of interest 
measurements can be performed. d. Color T1 map. T1 mapping can be displayed either on 
grayscale or a color map. The color of the pancreas is assessed by comparing it to the color 
scale (from 0 to 2000 ms) seen on the left side of this image
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Imaging and post-processing steps for creation of an ECV map. T1 relaxation times obtained 
from the pancreas and the aortic lumen (blood pool) in pre-contrast and 6-min delayed 
phases will be used to calculate the ECV fraction. T1 is a time constant describing the 
longitudinal relaxation rate, and its reciprocal (1/T1) is referred to as R1. The change in R1 
is ΔR1 = (R1post-contrast) – (R1pre-contrast). In the final step, ECV of the pancreas is calculated 
using ΔR1pancreas and ΔR1blood
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An example of MRE of the pancreas performed in a volunteer with the vibrational frequency 
of 60 Hz. A T2 localizer along with snapshots of curl processed waves to remove the 
longitudinal waves along one of the encoding directions and the stiffness map overlaid on 
the T2 localizer with a mean stiffness of 1.35 kPa in the pancreas
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